|
PT1087970E
(pt)
*
|
1998-06-19 |
2004-06-30 |
Pfizer Prod Inc |
Compostos pirrolo¬2,3-d|pirimidina
|
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
UA72290C2
(uk)
*
|
1999-12-10 |
2005-02-15 |
Пфайзер Продактс Інк. |
СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)
|
|
CN100351253C
(zh)
*
|
2000-06-26 |
2007-11-28 |
辉瑞产品公司 |
作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
|
|
CN1474815A
(zh)
|
2000-09-20 |
2004-02-11 |
Ĭ��ר���ɷ�����˾ |
4-氨基-喹唑啉
|
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
|
DE10063294A1
(de)
*
|
2000-12-19 |
2002-07-04 |
Aventis Pharma Gmbh |
Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
|
|
WO2002060492A1
(en)
*
|
2001-01-30 |
2002-08-08 |
Cytopia Pty Ltd |
Methods of inhibiting kinases
|
|
ATE305303T1
(de)
|
2001-02-12 |
2005-10-15 |
Hoffmann La Roche |
6-substituierte pyridopyrimidine
|
|
US7301023B2
(en)
*
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
|
GB0115393D0
(en)
*
|
2001-06-23 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
WO2003002106A2
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitions for treating allergic diseases
|
|
JP2004537537A
(ja)
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
|
|
JP2005500041A
(ja)
|
2001-06-29 |
2005-01-06 |
アブ サイエンス |
強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
|
|
US7678805B2
(en)
|
2001-06-29 |
2010-03-16 |
Ab Science |
Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
|
|
WO2003002109A2
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating autoimmune diseases
|
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
|
US7323469B2
(en)
|
2001-08-07 |
2008-01-29 |
Novartis Ag |
7H-pyrrolo[2,3-d]pyrimidine derivatives
|
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
|
GT200200234A
(es)
|
2001-12-06 |
2003-06-27 |
|
Compuestos cristalinos novedosos
|
|
ES2305435T3
(es)
|
2002-01-10 |
2008-11-01 |
Bayer Healthcare Ag |
Inhibidores de la rho-quinasa.
|
|
JP4423043B2
(ja)
|
2002-01-23 |
2010-03-03 |
バイエル ファーマセチカル コーポレーション |
Ｒｈｏ−キナーゼ阻害剤
|
|
JP4469179B2
(ja)
|
2002-01-23 |
2010-05-26 |
バイエル ファーマセチカル コーポレーション |
Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
|
|
GB0202679D0
(en)
*
|
2002-02-05 |
2002-03-20 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1388541A1
(en)
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazines as kinase inhibitors
|
|
KR20050086784A
(ko)
|
2002-11-26 |
2005-08-30 |
화이자 프로덕츠 인크. |
이식 거부반응의 치료 방법
|
|
CA2543116A1
(en)
*
|
2003-10-27 |
2005-05-19 |
Genelabs Technologies, Inc. |
Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
|
|
WO2005051393A1
(en)
*
|
2003-11-25 |
2005-06-09 |
Pfizer Products Inc. |
Method of treatment of atherosclerosis
|
|
CN101693695A
(zh)
*
|
2004-03-30 |
2010-04-14 |
大正制药株式会社 |
嘧啶衍生物以及与其应用有关的治疗方法
|
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
|
EP1768982A2
(en)
|
2004-06-29 |
2007-04-04 |
Amgen Inc. |
Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
|
|
BRPI0514094A
(pt)
|
2004-08-02 |
2008-05-27 |
Osi Pharm Inc |
composto, composição, e, método de tratamento de distúrbio hiperproliferativo
|
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
US7423043B2
(en)
*
|
2005-02-18 |
2008-09-09 |
Lexicon Pharmaceuticals, Inc. |
4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
|
|
EP1891066B1
(en)
|
2005-05-13 |
2010-12-22 |
Irm, Llc |
Compounds and compositions as protein kinase inhibitors
|
|
EP2251341A1
(en)
*
|
2005-07-14 |
2010-11-17 |
Astellas Pharma Inc. |
Heterocyclic Janus kinase 3 inhibitors
|
|
EP1910358A2
(en)
|
2005-07-14 |
2008-04-16 |
Astellas Pharma Inc. |
Heterocyclic janus kinase 3 inhibitors
|
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
|
NZ567133A
(en)
*
|
2005-09-30 |
2011-07-29 |
Vertex Pharma |
Deazapurines useful as inhibitors of janus kinases
|
|
DK3184526T3
(en)
|
2005-12-13 |
2019-01-14 |
Incyte Holdings Corp |
PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
|
|
EP2007373A4
(en)
*
|
2006-03-29 |
2012-12-19 |
Foldrx Pharmaceuticals Inc |
INHIBITION OF ALPHA SYNUCLEINE TOXICITY
|
|
US8796293B2
(en)
|
2006-04-25 |
2014-08-05 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
|
EP2121692B1
(en)
|
2006-12-22 |
2013-04-10 |
Incyte Corporation |
Substituted heterocycles as janus kinase inhibitors
|
|
KR20090106604A
(ko)
|
2007-01-12 |
2009-10-09 |
아스텔라스세이야쿠 가부시키가이샤 |
축합 피리딘 화합물
|
|
AU2008234822A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Palau Pharma, S. A. |
Pyrrolopyrimidine derivatives as JAK3 inhibitors
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
DK2740731T3
(en)
|
2007-06-13 |
2016-04-11 |
Incyte Holdings Corp |
CRYSTALLINE SALTS OF JANUSKINASEINHIBITOREN (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-CYCLOPENTYLPROPANNITRIL
|
|
DE102007027800A1
(de)
|
2007-06-16 |
2008-12-18 |
Bayer Healthcare Ag |
Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
|
|
CA2705319C
(en)
*
|
2007-11-10 |
2019-01-15 |
Laurence Reid |
Systems and methods for workflow automation, adaptation and integration
|
|
KR20100130583A
(ko)
*
|
2007-11-28 |
2010-12-13 |
다나-파버 캔서 인스티튜트 인크. |
Ｂｃｒ-ａｂｌ의 소 분자 미리스테이트 억제제 및 이의 사용 방법
|
|
CA2714177A1
(en)
|
2008-02-06 |
2009-08-13 |
Novartis Ag |
Pyrrolo [2,3-d] pyridines and use thereof as tyrosine kinase inhibitors
|
|
PL2247592T3
(pl)
*
|
2008-02-25 |
2012-01-31 |
Hoffmann La Roche |
Pirolopirazynowe inhibitory kinazy
|
|
BRPI0909040B8
(pt)
|
2008-03-11 |
2021-05-25 |
Incyte Holdings Corp |
derivados de azetidina e ciclobutano, seus usos, e composição
|
|
WO2009115084A2
(de)
*
|
2008-03-20 |
2009-09-24 |
Schebo Biotech Ag |
Neue pyrrolopyrimidin-derivate und deren verwendungen
|
|
JP2011526931A
(ja)
*
|
2008-07-03 |
2011-10-20 |
エグゼリクシス， インコーポレイテッド |
Ｃｄｋモジュレーター
|
|
US20110165183A1
(en)
*
|
2008-08-01 |
2011-07-07 |
Biocryst Pharmaceuticals, Inc. |
Piperidine derivatives as jak3 inhibitors
|
|
BRPI0917459B1
(pt)
*
|
2008-08-20 |
2017-09-12 |
Zoetis Services Llc |
N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
|
|
US8385364B2
(en)
*
|
2008-09-24 |
2013-02-26 |
Nec Laboratories America, Inc. |
Distributed message-passing based resource allocation in wireless systems
|
|
ES2552805T3
(es)
|
2009-04-20 |
2015-12-02 |
Auspex Pharmaceuticals, Llc |
Inhibidores piperidínicos de la cinasa Janus 3
|
|
MY156727A
(en)
|
2009-05-22 |
2016-03-15 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
AU2010249443B2
(en)
|
2009-05-22 |
2015-08-13 |
Incyte Holdings Corporation |
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
|
|
EP2451813B1
(en)
|
2009-07-08 |
2014-10-01 |
Leo Pharma A/S |
Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
|
|
TWI466885B
(zh)
|
2009-07-31 |
2015-01-01 |
Japan Tobacco Inc |
含氮螺環化合物及其醫藥用途
|
|
TW201111385A
(en)
*
|
2009-08-27 |
2011-04-01 |
Biocryst Pharm Inc |
Heterocyclic compounds as janus kinase inhibitors
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
KR101921850B1
(ko)
|
2009-10-09 |
2018-11-23 |
인사이트 홀딩스 코포레이션 |
3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
|
|
CA2776028C
(en)
*
|
2009-10-15 |
2015-12-01 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
ES2461967T3
(es)
|
2009-12-18 |
2014-05-21 |
Pfizer Inc. |
Compuestos de pirrolo[2,3-d]pirimidina
|
|
JP2013518882A
(ja)
|
2010-02-05 |
2013-05-23 |
ファイザー・インク |
ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物
|
|
EP2360158A1
(en)
*
|
2010-02-18 |
2011-08-24 |
Almirall, S.A. |
Pyrazole derivatives as jak inhibitors
|
|
AU2011224484A1
(en)
|
2010-03-10 |
2012-09-27 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
|
|
WO2012003829A1
(en)
*
|
2010-07-09 |
2012-01-12 |
Leo Pharma A/S |
Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
|
EP2640723A1
(en)
|
2010-11-19 |
2013-09-25 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
RU2013136906A
(ru)
|
2011-01-07 |
2015-02-20 |
Лео Фарма А/С |
Новые производные сульфамидпиперазина в качестве ингибиторов протеинтирозинкиназы и их фармацевтическое применение
|
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
|
CA2830882C
(en)
|
2011-03-22 |
2021-03-16 |
Dinesh Barawkar |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
|
MX2013013331A
(es)
*
|
2011-05-17 |
2014-10-17 |
Principia Biopharma Inc |
Derivados de azaindol como inhibidores de tirosina-cinasas.
|
|
KR20140040819A
(ko)
|
2011-06-20 |
2014-04-03 |
인사이트 코포레이션 |
Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
|
|
HK1198579A1
(en)
|
2011-08-10 |
2015-04-30 |
Novartis Pharma Ag |
Jak p13k/mtor combination therapy
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
|
RU2618673C2
(ru)
*
|
2011-12-21 |
2017-05-10 |
Цзянсу Хэнжуй Медсин Ко., Лтд. |
Производные пирролопиримидина, полезные в качестве ингибиторов jak-киназы
|
|
WO2013173720A1
(en)
|
2012-05-18 |
2013-11-21 |
Incyte Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
EP2852595B1
(en)
|
2012-05-21 |
2016-06-22 |
Bayer Pharma Aktiengesellschaft |
Substituted benzothienopyrimidines
|
|
KR20150027267A
(ko)
*
|
2012-06-29 |
2015-03-11 |
화이자 인코포레이티드 |
LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
|
|
ES2657912T3
(es)
*
|
2012-07-17 |
2018-03-07 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Indolcarbonitrilos como moduladores selectivos de los receptores de andrógenos
|
|
SI2874630T1
(sl)
*
|
2012-07-20 |
2019-04-30 |
Zoetis Services Llc |
Odmerni režim inhibitorjev Janus kinaz (JAK)
|
|
TW201412740A
(zh)
|
2012-09-20 |
2014-04-01 |
Bayer Pharma AG |
經取代之吡咯并嘧啶胺基苯并噻唑酮
|
|
WO2014045305A1
(en)
|
2012-09-21 |
2014-03-27 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
|
CN102936251A
(zh)
*
|
2012-11-05 |
2013-02-20 |
上海毕得医药科技有限公司 |
一种吡咯并[2,3-d]嘧啶衍生物的制备方法
|
|
PH12020551186B1
(en)
|
2012-11-15 |
2024-03-20 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
|
KR101683061B1
(ko)
*
|
2013-02-07 |
2016-12-07 |
한국과학기술연구원 |
ＪＡＫ-3 저해제로 유용한 ７Ｈ-피롤로[2,3-ｄ]피리미딘-4-싸이올 유도체
|
|
MY177476A
(en)
|
2013-02-22 |
2020-09-16 |
Pfizer |
Pyrrolo [2,3-d]pyrimidine derivatives as inhibitors of janus kinases (jak)
|
|
JP6397831B2
(ja)
|
2013-03-06 |
2018-09-26 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｊａｋ阻害剤の製造方法及びその中間体
|
|
WO2014139388A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
KR20160045081A
(ko)
|
2013-08-07 |
2016-04-26 |
인사이트 코포레이션 |
Jak1 억제제용 지속 방출 복용 형태
|
|
MD4649C1
(ro)
|
2013-12-05 |
2020-04-30 |
Pfizer Inc. |
Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
|
|
US9695171B2
(en)
|
2013-12-17 |
2017-07-04 |
Pfizer Inc. |
3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
EP3180344B1
(en)
|
2014-08-12 |
2019-09-18 |
Pfizer Inc |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
WO2016178110A1
(en)
|
2015-05-01 |
2016-11-10 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
|
|
MX381994B
(es)
*
|
2015-05-29 |
2025-03-13 |
Wuxi Fortune Pharmaceutical Co Ltd |
Inhibidor de janus quinasa.
|
|
KR101771219B1
(ko)
*
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
|
JP6873980B2
(ja)
|
2015-09-14 |
2021-05-19 |
ファイザー・インク |
ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
|
|
CN106831779B
(zh)
*
|
2015-11-28 |
2019-07-19 |
南昌弘益药业有限公司 |
一类jak激酶抑制剂的新化合物
|
|
JP6568324B2
(ja)
|
2016-02-16 |
2019-08-28 |
ゾエティス・サービシーズ・エルエルシー |
７Ｈ−ピロロ［２，３−ｄ］ピリミジン化合物の調製方法
|
|
CN107098908B
(zh)
*
|
2016-02-23 |
2021-01-08 |
欣凯医药科技(上海)有限公司 |
一种吡咯并嘧啶类化合物的制备方法和应用
|
|
EP3555074B1
(en)
|
2016-12-14 |
2022-07-27 |
Intervet International B.V. |
Aminopyrazoles as selective janus kinase inhibitors
|
|
JP6944496B2
(ja)
|
2018-10-22 |
2021-10-06 |
ファイザー・インク |
ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
|
|
BR112021008742A2
(pt)
|
2018-11-05 |
2021-08-10 |
Avista Pharma Solutions, Inc. |
compostos químicos
|
|
TW202043205A
(zh)
|
2018-12-31 |
2020-12-01 |
美商拜歐米富士恩有限公司 |
Menin-mll相互作用之抑制劑
|
|
MX2021007925A
(es)
|
2018-12-31 |
2021-10-26 |
Biomea Fusion Llc |
Inhibidores irreversibles de la interaccion menina-mll.
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
CN113993585B
(zh)
|
2019-03-27 |
2024-10-01 |
英矽智能科技知识产权有限公司 |
双环jak抑制剂及其用途
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
JP2023554665A
(ja)
|
2020-12-18 |
2023-12-28 |
ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド |
ホウ素含有ピラゾール化合物、それらを含む組成物、それらの方法及び使用
|
|
CA3228627A1
(en)
|
2021-08-11 |
2023-02-16 |
Thomas Butler |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
|
CN119816500A
(zh)
|
2021-08-20 |
2025-04-11 |
拜欧米富士恩公司 |
用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式
|
|
WO2023029943A1
(zh)
*
|
2021-09-03 |
2023-03-09 |
星药科技(北京)有限公司 |
一种芳杂环化合物及其制备方法和用途
|
|
US20250051337A1
(en)
*
|
2021-09-28 |
2025-02-13 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
|
|
AU2022418280A1
(en)
|
2021-12-24 |
2024-06-13 |
Intervet International B.V. |
Use of aminopyrazole compounds
|
|
GB202215117D0
(en)
*
|
2022-10-13 |
2022-11-30 |
Norwegian Univ Sci & Tech Ntnu |
Compound
|
|
GB202215132D0
(en)
*
|
2022-10-13 |
2022-11-30 |
Norwegian Univ Sci & Tech Ntnu |
Compound
|
|
WO2024155719A1
(en)
|
2023-01-18 |
2024-07-25 |
Biomea Fusion, Inc. |
Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction
|